Seller record · Telehealth service

RegenCen

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published on the weight loss page, the peptide page or the about page. 1 more criterion also fails; see the table below.

At a glance

RegenCenTelehealth service

5/8criteria passed

Price: Not printed before a consultation or sign-up
Sells: semaglutide, tirzepatide, sermorelin, and 3 more
FDA letters: None on file

Visit RegenCen See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. 1 not verified, counting neither way. Recorded against Standard v1.1.

A Michigan and Florida network of hormone and regenerative medicine clinics, with telehealth visits in both states, that offers semaglutide and tirzepatide weight loss programs, sermorelin, NAD+ injections and bioidentical hormone therapy after a free consultation.

Operating entity No operating entity is named in the footer, on the contact page or on the about page, and the site links no terms or privacy page; the footer says only that the RegenCen mark is registered by CSLC MSO Buyer, LLC.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	RegenCen's peptide therapy product page; RegenCen's treatments weight loss page
S2	Prescription gating	PASS	RegenCen's treatments weight loss page; RegenCen's telehealth page
S3	Pharmacy identification	PASS	RegenCen's telehealth page
S4	Compounding disclosure	NOT VERIFIED	RegenCen's treatments weight loss page; RegenCen's peptide therapy product page
S5	Analytical documentation	FAIL	RegenCen's treatments weight loss page; RegenCen's peptide therapy product page; RegenCen's about page
S6	Business address	PASS	RegenCen's petoskey MI page; RegenCen's contact page
S7	Price disclosure	FAIL	RegenCen's treatments weight loss page; RegenCen's peptide therapy product page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSLicensed medical providers under the clinical guidance of Dr. Gustav Lo, MD evaluate each patient, with labs ordered before prescribing, and prescriptions for semaglutide or tirzepatide come with ongoing provider check-ins.Source: RegenCen's peptide therapy product page; RegenCen's treatments weight loss page.

S2PASSEvery program starts with a complimentary consultation and lab work, followed by plan selection and then medication, in person or by telehealth.Source: RegenCen's treatments weight loss page; RegenCen's telehealth page.

S3PASSThe telehealth answers name Belmar, at 231 Violet St, Suite 140, Golden, Colorado, as the pharmacy the clinic works with.Source: RegenCen's telehealth page.

S4NOT VERIFIEDA statement of whether the semaglutide and tirzepatide sold are compounded did not resolve, because the weight loss and peptide pages name the drugs without saying whether they are brand-name or compounded, and the word compounded appears only about peptides the clinic does not offer. The check is open.Source: RegenCen's treatments weight loss page; RegenCen's peptide therapy product page.

S5FAILNo certificate of analysis or lot document is published on the weight loss page, the peptide page or the about page.Source: RegenCen's treatments weight loss page; RegenCen's peptide therapy product page; RegenCen's about page.

S6PASS116 W Mitchell St, Petoskey, MI 49770, printed on the Petoskey clinic page with the telephone number used across the site, one of more than twenty clinic addresses in Michigan and Florida.Source: RegenCen's petoskey MI page; RegenCen's contact page.

S7FAILNo price is printed. The weight loss answers say the provider walks the patient through pricing during the complimentary consultation, and the peptide answers say pricing is given during the consultation.Source: RegenCen's treatments weight loss page; RegenCen's peptide therapy product page.

S8PASSNo FDA warning letter names RegenCen or CSLC MSO Buyer, LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: semaglutide, tirzepatide, sermorelin, NAD+ injections, B Fit Shot+, bioidentical hormone replacement therapy.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+

Visit RegenCen

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.